Immatics and Molmed become the subjects of very different deals
Two acquisitions of cell therapy companies could take them in almost opposite directions.
Kiadis falls, and Bellicum could be next
EU rejection of Kiadis's stem cell transplant adjunct means that two of three players in this space have been knocked back.
Twilight of the stem cell transplant adjuncts?
The ripples of Molmed’s pivotal study failure could stretch beyond the company’s Zalmoxis product.
Mustang and the bubble boy bubble
The value of Mustang Bio has tripled on data on its immune deficiency gene therapy. But investors might be too keen – and also too late.
Kiadis moves to reduce reliance on its in-house lead
Perhaps sensing trouble ahead Kiadis diversifies beyond ATIR101 by buying Cytosen, but it is a scientific appointment that will cause real excitement.
